Metastatic Breast Cancer Video Perspectives
Sara M. Tolaney, MD, MPH
Tolaney reports consulting or advising for Aadi Biopharma, ARC Therapeutics, Artios Pharma, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, CytomX Therapeutics, Daiichi Sankyo, Eisai, Eli Lilly, Genentech/Roche, Gilead, Jazz Pharmaceuticals, Incyte Corp, Infinity Therapeutics, Natera, Menarini/Stemline, Merck, Myovant (now Sumitovant Biopharma), Novartis, OncXerna, Pfizer, Reveal Genomics, Sanofi, Seattle Genetics, Umoja Biopharma, Zentalis, Zetagen and Zymeworks; and receiving research funding from AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Eisai, Exelixis, Genentech/Roche, Gilead, Lilly, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer and Seattle Genetics.
VIDEO: Highlights in the latest treatments for metastatic breast cancer
Transcript
Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.
It is really exciting to see that there have actually been a number of advancements for our patients with metastatic disease. Some, just to highlight, would be the availability now of immunotherapies, specifically for patients with metastatic triple-negative disease. Additionally, we've seen the introduction of novel antibody-drug conjugates. So we had traditionally had Trastuzumab emtansine (Kadcyla, Genentech), or T-DM1, approved in metastatic HER2-positive disease. But, now we have T-DXd (Enhertu, AstraZeneca, Daiichi Sankyo) approved, both for metastatic HER2-positive as well as metastatic HER2-low breast cancer, and we have sacituzumab govitecan (Trodelvy, Gilead Sciences), an antibody-drug conjugate targeting TROP-2, that is approved both for metastatic triple-negative and metastatic hormone-receptor positive disease. There are also multiple new antibody-drug conjugates in development, so I think we'll see more of those to come.
We've also seen multiple targeted agents get approved for metastatic disease. For a few years now, we've had CDK4/6 inhibitors. We've have protein kinase inhibitors, mTOR inhibitors. But now, hopefully, we'll see an approval soon for capivasertib (AZD5363, AstraZeneca), an oral AKT inhibitor, and then we recently got approval for elacestrant (Orserdu, Stemline Therapeutics), an oral selective estrogen receptor degrader, in patients who have metastatic ER-positive disease and an ESR1 mutation. So as you can see, there are really lots of novel therapies that have come along that really are having a huge impact on outcomes for a metastatic breast cancer patient.
